ASH 2024 Summary: MPN Highlights and Clinical Implications

2024 ASH Annual Meeting Insights Hub

D. Tremblay

ASH 2024 Summary: Highlights in CML

2024 ASH Annual Meeting Insights Hub

J. Yang

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How

2024 ASH Annual Meeting Insights Hub

J. Kiladjian

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Myelofibrosis: Diagnosis, Clinical Manifestations, Treatment Approac…

Amy Zhou

Momelotinib in MF: Insights from SIMPLIFY-1, SIMPLIFY-2, and MOMENTU…

Jeanne Palmer

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Allele Burden in MPN: Practical Considerations

16th International Congress on Myeloproliferative Neoplasms

R. Rampal

Novel Agents for MPNs in 2024

16th International Congress on Myeloproliferative Neoplasms

N. Pemmaraju

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Rux…

2024 ASH Annual Meeting Insights Hub

J. Mascarenhas

Overview of Myelofibrosis: Management, JAK Inhibitor Trials, and Eme…

Akhil Jain

Treatment Landscape of JAK Inhibitors in Myelofibrosis

Juliana Schwaab

Current and Future Treatment Landscape of Myelofibrosis

XV Eurasian Hematology-Oncology Congress - EHOC 2024

R. Komrokji

Overview of Myelofibrosis: Diagnosis, Current Therapies, Symptom Con…

Robert Peter Gale

COMFORT-1 Trial Long-Term Follow-Up: Impact of Ruxolitinib on OS for…

Winship Cancer Institute - Emory University

A. Hunter